The 14th Five-Year Plan: Re-Entrepreneurship—Gathering Momentum for a New Journey of Long-Term Vision‖ The 2025 Year-End Summary and 2026 Work Deployment Meeting of Guizhou Ruihe Pharmaceutical was successfully held.

On January 14, 2026, Guizhou Ruihe Pharmaceutical Co., Ltd. successfully held its 2025 Year-End Summary and 2026 Work Deployment Meeting at the Ruihe Greater Health Industrial Park. Centered around the theme “Re-launching Entrepreneurship under the ‘14th Five-Year Plan’ and Seizing New Opportunities for a Long-term Journey,” the meeting comprehensively reviewed the achievements of 2025’s work, accurately analyzed new trends and opportunities in the pharmaceutical industry, and systematically outlined the company’s strategic development blueprint for the “14th Five-Year Plan” period, thereby setting the course and rallying collective strength for the next stage of high-quality development. The meeting was chaired by Zhao Yun, the company’s General Manager, and attended by all core management personnel and key employees.

At the outset of the meeting, Xiong Yigang, Chairman of the company, delivered an opening address, extending heartfelt gratitude and best wishes for the New Year to all Ruihe colleagues who have worked diligently throughout the past year. He also highly recognized the team’s significant achievements made in 2025 as they tackled challenges and pressed forward with determination. In his speech, Chairman Xiong Yigang comprehensively reviewed the company’s development journey since the implementation of the “13th Five-Year Plan,” objectively analyzed the strengths and weaknesses of past efforts, and, in light of current national policies guiding the pharmaceutical industry, the evolving market competition landscape, and the trend toward industrial innovation and transformation, clearly defined the core strategic objectives and implementation roadmap for the “14th Five-Year Plan.”

He emphasized that 2026, as the inaugural year of the company’s “14th Five-Year Plan,” is a pivotal moment for solidifying the foundation of our development and accumulating momentum for growth. Faced with the profound transformation driven by innovation in the pharmaceutical industry and the ongoing normalization of compliance regulations—challenges that are both daunting and critical—every member of Ruihe embodies a spirit of boldness and willingness to explore new frontiers, coupled with a pragmatic and truth-seeking work ethic. In key areas such as drug R&D, production quality control, market expansion, and core team building, we are forging ahead with determination and working collaboratively to overcome challenges, steadily driving the company toward simultaneous improvements in scale and quality, as well as speed and efficiency.

Subsequently, the heads of various departments took to the stage one by one to deliver detailed reports on the completion status of key tasks for 2025, the existing problems, and proposed improvement measures. In conjunction with the company’s overall strategy, they made specific arrangements for their departments’ 2026 work objectives, priority tasks, and implementation plans. The on-site exchanges were practical, in-depth, and highly focused, fostering a shared understanding and coordinated efforts across all levels of the organization.

The successful convening of this conference not only systematically reviewed the achievements made in 2025 and clarified our development strategy, but also clearly outlined the key priorities and direction for 2026. The conference further fostered consensus among all employees and boosted team morale, injecting strong momentum into the company’s deepened implementation of the “14th Five-Year Plan,” its continued深耕 in the pharmaceutical and healthcare sector, and its pursuit of high-quality, leapfrog development. Taking this conference as an opportunity, all Ruihe employees will embrace the passion of starting anew and adopt a long-term strategic perspective, uniting their hearts and minds, staying committed to practical action, and jointly writing a new chapter in the development of Ruihe Pharmaceutical.